ArticleMolecular pharmacology2026
Elucidating molecular mechanisms governing tumor necrosis factor-alpha-mediated regulation of amyloid beta 42 uptake in blood-brain barrier endothelial cells.
Article in Molecular pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The role of TNF signaling pathway in post-stroke cognitive impairment: a systematic review.Annals of medicine · 2025Pooled it
- Immunosuppressant Use Mediates Neuroprotection Against Alzheimer's Disease in Rheumatoid Arthritis-A Two-Step Mendelian Randomization and NHANES Study.International journal of rheumatic diseases · 2026Article
- Acute amyloid-β exposure disrupts insulin signaling in hCMEC/D3 blood-brain barrier endothelial cells.Fluids and barriers of the CNS · 2026Article
- Bidirectional interactions along the microbiota-gut-brain axis in radiation-induced brain injury: mechanisms and therapeutic insights.Frontiers in oncology · 2026Review
- The missing link: TNF-α as a unifying mechanism in methamphetamine-induced neuronal dysfunction and blood-brain barrier compromise.Journal of neuroimmunology · 2025Review
Corrections and comments
- Update of
Authors and funding
6 authors.
Funding
Abstract
Cerebrovascular inflammation is prevalent in a majority of patients with Alzheimer disease. Elevated levels of inflammatory cytokines, such as tumor necrosis factor-α (TNF-α), circulating in the plasma have been shown to cause the inflammation of blood-brain barrier (BBB) endothelium lining the cerebral microvasculature in Alzheimer disease. The BBB inflammation triggered by exposure of TNF-α in the peripheral circulation can aggravate the accumulation of Aβ peptides in Alzheimer disease brain. In the current study, we have shown that infusion of wild-type mice with TNF-α led to an increase in permeability and influx of Aβ42 into the mice brain using dynamic single-photon emission computed tomography/computed tomography imaging. To corroborate these findings, we demonstrated that TNF-α increases Aβ42 accumulation in vitro in human cerebral microvascular endothelial cells /D3 and primary porcine brain endothelial cells. In addition, our results in human cerebral microvascular endothelial cells/D3 polarized monolayers show that TNF-α alters the expression of cofilin, actin, and dynamin, which are critical components for Aβ endocytosis by BBB endothelial cells. These results suggest a mechanistic pathway by which TNF-α may promote Aβ accumulation at the BBB and the underlying interactions between inflammation and Aβ exposure that drives BBB dysfunction. Hence, a therapeutic intervention aimed at addressing elevated TNF-α levels in Alzheimer disease may potentially reduce Aβ-related cerebrovascular dysfunction in Alzheimer disease brain. SIGNIFICANCE STATEMENT: Elevated plasma tumor necrosis factor-α drives Aβ pathology in Alzheimer disease, promoting cerebrovascular inflammation, but its role in endothelial Aβ uptake in the brain is unclear. This study shows tumor necrosis factor-α increases Aβ42 accumulation in the blood-brain barrier endothelium by altering the expression of blood-brain barrier endocytic proteins cofilin, actin, and dynamin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.